Researchers at IBEC help identifying a drug in clinical phase that blocks the effects of SARS-Co-V2
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
The treatment, which can be tested on two hundred Covid-19 patients as of today, has proven effective in mini-kidneys generated from human stem cells. Using hese organoids generated by bioengineering techniques, it has been deciphered how SARS-Co-V2 interacts and infects human kidney cells.
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
The Institute for Bioengineering of Catalonia (IBEC) will contribute its extensive experience in 3D printing and bioprinting to the BASE 3D community, an entity that brings together research centers and companies from all over Catalonia with the aim of promoting R+D+i in the field of printing 3D.
Three IBEC projects have been selected to receive funding from “La Marató 2018: Against Cancer.” One of the projects is led by the researcher Pere Roca-Cusachs and the other two are co-led by the researchers Xavier Trepat and Núria Montserrat.

On Monday IBEC junior group leader Nuria Montserrat and senior researcher Aranzazu Villasante were two of the researchers awarded funding at the Asociación Española de Investigación sobre el Cáncer (AECC)’s ceremony in Madrid.